Intra-Cellular Therapies, Inc.
ITCI
Classement en actions
#1690
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Prix de l'action
$131.87
Dernière synchronisation: 2025-04-02
Capitalisation boursière
$12.68B
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Intra-Cellular Therapies, Inc. (ITCI)
Catégorie
Healthcare
Revenus pour Intra-Cellular Therapies, Inc. (ITCI)
Revenus en Dec 2024 TTM : $680.64M
Selon les derniers rapports financiers de Intra-Cellular Therapies, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $680.64M. En 2023, l'entreprise a réalisé un chiffre d'affaires de $464.37M une augmentation par rapport à le chiffre d'affaires de l'année 2022, qui était de $249.13M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Intra-Cellular Therapies, Inc. de 2013 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $680.64M | -0.03% |
| 2024 | $680.85M | 46.62% |
| 2023 | $464.37M | 86.40% |
| 2022 | $249.13M | 204.91% |
| 2021 | $81.71M | 262.65% |
| 2020 | $22.53M | 37,071.49% |
| 2019 | $60.61K | 0.00% |
| 2018 | 0.00 | -100.00% |
| 2017 | $245.84K | -25.66% |
| 2016 | $330.70K | 261.96% |
| 2015 | $91.36K | -84.17% |
| 2014 | $577.30K | -78.91% |
| 2013 | $2.74M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 871.39% |
IN
|
